JOE
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1677/joe.0.1720683

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lambertini, E
Right arrow Articles by Piva, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lambertini, E
Right arrow Articles by Piva, R
Journal of Endocrinology, Vol 172, Issue 3, 683-693
Copyright © 2002 by Society for Endocrinology


Articles

Modulation of gene expression in human osteoblasts by targeting a distal promoter region of human estrogen receptor-alpha gene

E Lambertini, L Penolazzi, V Sollazzo, F Pezzetti, M de Mattei, L del Senno, GC Traina, and R Piva


Estrogen receptor (ER) alpha is expressed during osteoblast differentiation; however, both its functional role in bone metabolism and its involvement in osteoporotic pathogenesis caused by estrogen deficiency are not well understood. Loss of ER alpha gene expression could be one of the mechanisms leading to osteoporosis. Therefore, we investigated a possible modulation of ER alpha gene expression in a human osteoblastic cell line and in four primary osteoblast cultures by using a decoy strategy. Double stranded DNA molecules, mimicking a regulatory region of the ER alpha gene promoter (DNA-102) and acting as a 'silencer' in breast cancer cells, were introduced into osteoblasts as 'decoy' cis-elements to bind and functionally inactivate a putative negative transcription factor, and thus to induce ER alpha gene expression. We found that the DNA-102 molecule was able to specifically bind osteoblast nuclear proteins. Before decoy treatment, absence or variable low levels of ER alpha RNAs in the different cultures were detected. When the cells were transfected with the DNA-102 decoy, an increase in expression of ER alpha and osteoblastic markers, such as osteopontin, was observed, indicating a more differentiated osteoblastic phenotype both in the cell line and in primary cultures. These results showed that the DNA-102 sequence competes with endogenous specific negative transcription factors that may be critical for a decrease in or lack of ER alpha gene transcription. Therefore, osteoblastic transfection with the DNA-102 decoy molecule may be considered a tempting model in a putative therapeutic approach for those pathologies, such as osteoporosis, in which the decrease or loss of ER alpha expression plays a critical role in bone function.


This article has been cited by other articles:


Home page
J. Dent. Res.Home page
P. Sibilla, A. Sereni, G. Aguiari, M. Banzi, E. Manzati, C. Mischiati, L. Trombelli, and L. del Senno
Effects of a Hydroxyapatite-based Biomaterial on Gene Expression in Osteoblast-like Cells.
J. Dent. Res., April 1, 2006; 85(4): 354 - 358.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
V. J. Dzau
Transcription Factor Decoy
Circ. Res., June 28, 2002; 90(12): 1234 - 1236.
[Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Society for Endocrinology.